RELATED CONTENT
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago.
September 13, 2019 
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medical ...
August 14, 2019 
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not-for-profit health system based in Louisiana.
June 12, 2018 IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
June 07, 2018 May 24, 2012 — IsoRay Inc., a medical technology company in seed brachytherapy and medical radioisotope applications, announced that the GliaSite radiation therapy system, the world's only balloon catheter device used in the treatment of brain cancer, has earned the European CE Mark.
May 24, 2012 May 7, 2012 - IsoRay Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced it will host a booth at the world brachytherapy meeting. The program, presented by GEC-ESTRO (The
Groupe Européen de Curiethérapie and the European Society for Therapeutic Radiology and Oncology), in co-operation with ABS (American Brachytherapy Society), ALATRO (Asociacion Latinoamericana de Terapia Radiante Oncologica), and the Indian and Australasian brachytherapy groups, will take place May 10-12 in Barcelona, Spain.
May 07, 2012 February 9, 2012 — IsoRay Inc., a medical technology company with specialty in seed brachytherapy and medical radioisotope applications, said that the findings of a Cleveland Clinic study add to evidence supporting the efficacy of brachytherapy.
February 09, 2012 October 28, 2010 – An initial feasibility study has demonstrated the ability to use cesium-131 (Cs-131) brachytherapy seeds in accelerated partial breast irradiation (APBI) for breast cancer treatment. The study looked at IsoRay’s patented therapy for treating early stage, localized breast cancer.
October 28, 2010 
IsoRay Medical Inc.’s Proxcelan is a seed used in low dose radiation (LDR) permanent brachytherapy for prostate cancer ...
June 04, 2008 IsoRay Medical Inc.’s Proxcelan is a seed used in low dose radiation (LDR) permanent brachytherapy for prostate cancer ...
April 08, 2008